Breast cancer is the most widespread carcinoma in the United Kingdom, accounting for 15% of all cancer diagnoses. This alarming statistic means 150 individuals across the UK are diagnosed with carcinoma daily. Unfortunately, 31 of these individuals will lose their fight against the disease, making it the leading cause of death among women aged 35-49.
Cancer usually originates in the ducts or lobes of the breast and spreads into surrounding breast tissue. If the carcinoma remains within the lobes or ducts, it is called ductal carcinoma in situ (DCIS). DCIS is not life-threatening if treated appropriately, but it can still cause concern. The most common type of invasive breast cancer is invasive ductal carcinoma, which has a higher potential for spreading to other body parts. In comparison, invasive lobular carcinoma is less common but can also extend beyond the breast tissue.
There are also rarer types of breast cancer, such as Paget’s disease of the breast, which causes the red, scaly skin rash of the nipple and is often associated with DCIS. Another rare form is inflammatory breast cancer, which results in the breast becoming inflamed and swollen, often without a detectable lump.
The prevalence of breast cancer in the UK highlights the importance of early detection, as early diagnosis significantly improves the chances of successful treatment and survival. Regular self-examinations and mammograms can help identify potential breast abnormalities or changes that may warrant further investigation.
Advancements in research and technology have led to improved treatments for breast cancer, including surgery, radiation therapy, chemotherapy, hormonal therapy, and targeted therapy. The choice of treatment largely depends on the stage of cancer, the patient’s overall health, and personal preferences.
You are here:
home »
By
| 5 minutes of readingChemotherapy for cancer treatment targets rapidly growing cancer cells but can also harm healthy cells, causing side effects.
Chemotherapy to Treat Cancer: How Does It Work? Read Article »
By
| 7 minutes of readingTumour grading assesses cellular abnormality, predicting cancer growth rate, treatment needs, and informing patient prognosis effectively.
Decoding Cancer: How the Tumour Grading System Shapes Diagnosis and Treatment Read Article »
By
| 7 minutes of readingMachine learning with MRI radiomics offers promise for non-invasive lymphovascular invasion prediction in breast cancer, but limitations require further refinement.
By
| 4 minutes of readingExploring Lutetium-177 AMTG highlights its innovative design, enhanced metabolic stability, and potential for effectively treating GRPR-positive prostate and breast tumours.
By
| 6 minutes of readingRadioactive cancer therapies utilise targeted radiation to damage tumour DNA, halting their growth and preventing further spread.
Radioactive Cancer: Harnessing Radiation in the Fight Against Malignancy Read Article »
By
| 8 minutes of readingThis article explores cancer treatment advancements, tumour biology complexities, and the critical role of palliative care in oncology.
Advances in Oncology: Cancer Treatment, Tumour Biology, and Palliative Care Read Article »
By
| 5 minutes of readingAdvancements in medical imaging technology are transforming cancer diagnosis, enabling more precise treatment planning and better patient outcomes.
Revolutionising Cancer Care: The Power of Medical Imaging Read Article »
By
| 5 minutes of readingTactile imaging transforms diagnostics by converting tactile sensations into visual data, enabling precise, non-invasive detection of tissue abnormalities and conditions.
Tactile Imaging: Transforming Diagnostic Medicine Through the Sense of Touch Read Article »
By
| 3 minutes of readingIodine-131 CAM-H2 heralds a new era in oncology, offering hope through precise targeting of HER2-expressing cancers with minimal side effects.
Exploring Iodine-131 CAM-H2 for Treating HER2-Expressing Cancers Read Article »
By
| 3 minutes of readingEstrogen receptor targeting agents, including Fluorine-18 and Iodine-131 analogues, revolutionise breast cancer diagnostics, therapeutics, and personalised patient management.
By
| 3 minutes of readingActinium-225 is a rare, promising isotope revolutionizing targeted alpha therapy for various resistant cancers.
Actinium-225: The Emerging Star in Targeted Alpha Therapy Read Article »
By
| 4 minutes of readingRadiomics offers non-invasive, quantitative image analysis for predicting breast cancer patients’ response to neoadjuvant chemotherapy, enhancing personalised treatment.
Predicting Neoadjuvant Chemotherapy Response in Breast Cancer Patients Read Article »
By
| 3 minutes of readingFluorine-18 Fluoroestradiol PET imaging enables early breast cancer detection, accurate staging, and treatment response monitoring, improving patient outcomes.
Fluorine-18 Fluoroestradiol: A Promising Tool for Breast Cancer Imaging Read Article »
By
| 5 minutes of readingThe diagnostic breast imaging tool Positron Emission Mammography uses short-lived positron isotopes to detect breast cancer.
The Role Of Positron Emission Mammography In Breast Cancer Imaging Read Article »
By
| 19 minutes of readingNeuroendocrine tumours include a spectrum of neoplasms characterized by histologic heterogeneity.
[18F]-Estradiol PET/CT imaging in breast cancer patients Read Article »
